Integral Molecular is actively building a portfolio of therapeutic antibodies against under-exploited membrane protein targets. We focus on antibody discovery, lead optimization, and in vivo proof-of-concept to offer pre-IND molecules for licensing.
We welcome partnerships with companies interested in developing highly differentiated preclinical antibodies into first-in-class therapeutics in the areas of pain, immunity, metabolic diseases, oncology, and infectious diseases. Antibodies developed at Integral Molecular are fully humanized, designed to recognize both human and rodent orthologs, and demonstrate potency in animal disease models. Integral Molecular also partners for co-discovery of new antibodies and targets using its proprietary technologies.
Please contact us at to discuss licensing opportunities.